Visceral Adipose Tissue (VAT): What This Test Actually Measures

What VAT Actually Is (and Why It Is Different From Subcutaneous Fat)

Your body stores fat in two main depots: just under the skin (subcutaneous) and deep inside the abdomen (visceral). VAT is the deeper depot. It sits inside the peritoneal cavity, tucked around your liver, pancreas, intestines, and kidneys. You cannot pinch it. A scale cannot distinguish it from muscle. Even a normal BMI does not rule it out.

The distinction matters clinically because VAT is not metabolically inert tissue. It releases free fatty acids directly into the portal vein, sending a continuous lipid load straight to the liver. Research published in Arteriosclerosis, Thrombosis, and Vascular Biology confirms that portal free fatty acid flux from VAT drives hepatic insulin resistance and dyslipidemia more strongly than subcutaneous fat does. That direct portal drainage is the core reason VAT carries risks that subcutaneous fat largely does not.

What the Test Measures

A DEXA (dual-energy X-ray absorptiometry) scan separates your body into bone mineral, lean mass, and two fat compartments. The software algorithm uses the attenuation difference between visceral and subcutaneous fat to estimate the VAT volume in the android (abdominal) region. Results are typically reported as grams of fat or, when converted, as an estimated cross-sectional area in cm².

CT imaging at the L4-L5 lumbar level remains the reference standard for VAT area measurement, and a landmark validation study showed DEXA-derived VAT correlates with CT-measured VAT at r = 0.80 in women. That is strong enough for clinical use, and DEXA exposes you to far less radiation than CT (roughly 10 microsieverts versus 5,000-8,000 microsieverts).

MRI is the gold standard for research but is expensive and not routine in clinical practice.

What It Does Not Measure

VAT measurement does not capture:

• Ectopic fat in the liver (hepatic steatosis requires ultrasound or MRI-PDFF)
• Pericardial or epicardial fat (requires cardiac imaging)
• Intramuscular fat (measured by MRI spectroscopy)
• Subcutaneous fat distribution (reported separately on DEXA as subcutaneous adipose tissue, or SAT)

The VAT-to-SAT ratio is sometimes reported and carries independent predictive value. A high VAT with low SAT (thin subcutaneous padding but deep visceral accumulation) is particularly high risk.

Normal VAT Ranges for Women

No single universal threshold exists, partly because reference ranges depend on the DEXA device manufacturer, the software version, and the population studied. That is an honest limitation you deserve to know.

The most widely cited clinical thresholds come from large epidemiological cohorts. The Framingham Heart Study offspring cohort found that a VAT area >100 cm² in women was associated with significantly elevated odds of metabolic syndrome, hypertension, and dyslipidemia. Many clinical labs use this 100 cm² threshold as their risk cut-point for women, though some use 80 cm² for Asian women, who accumulate cardiometabolic risk at lower absolute VAT levels.

Ranges by Life Stage

| Life Stage | Approximate Low-Risk Range (VAT area) | |---|---| | Premenopausal women (20-45 yr) | <80 cm² | | Perimenopausal women (45-55 yr) | <100 cm² | | Postmenopausal women (>55 yr) | <120 cm² (some guidelines use <100 cm²) | | Women with PCOS | Interpret at the lower threshold |

These are guideline-informed estimates, not FDA-cleared diagnostic cut-points. Your clinician should interpret your result in the context of your full metabolic panel, not as a stand-alone number.

The "Normal Weight Obese" Pattern

Roughly 30 million American women have a BMI in the normal range but elevated VAT. A study in the European Heart Journal found that normal-weight adults with high VAT had a cardiovascular mortality risk equivalent to that of obese individuals. This is sometimes called "metabolically obese, normal weight" or "MONW." It is one reason VAT measurement adds clinical information that BMI alone cannot provide.

How Hormones and Life Stage Change Your VAT

This is where women's biology diverges sharply from the male-default clinical literature. Most early VAT research was conducted in men. The physiology in women is distinct, and the hormonal drivers are worth understanding in detail.

Reproductive Years (Ages 20-44)

Estrogen actively suppresses VAT accumulation. Estrogen receptors on visceral adipocytes inhibit fat storage in the abdominal depot and direct excess energy toward subcutaneous storage, particularly in the hips and thighs. This is why premenopausal women, on average, carry less VAT than age-matched men at equivalent total body fat percentages.

Data from the CARDIA (Coronary Artery Risk Development in Young Adults) study showed that premenopausal women had significantly lower VAT than men even at similar BMI values, an advantage that narrows progressively through the menopause transition.

Trying to Conceive and Fertility

High VAT impairs fertility. The mechanism involves VAT-derived cytokines (TNF-alpha, IL-6) disrupting hypothalamic-pituitary-ovarian signaling and impairing oocyte quality. A study in Fertility and Sterility found that visceral adiposity predicted poor IVF outcomes independently of total body weight. If you are trying to conceive and have high VAT, reducing it before your cycle improves the hormonal environment even if your overall weight does not change much.

Perimenopause (Ages 40-55)

Perimenopause is the most significant driver of VAT change in a woman's lifetime. As estrogen levels fluctuate and decline, the suppression of visceral fat accumulation lifts. Fat redistribution shifts from the gluteal-femoral depot (hips and thighs) toward the abdominal depot.

The Study of Women's Health Across the Nation (SWAN) found that VAT increased by an average of 49% during the menopause transition, with the steepest rise occurring in the two years surrounding the final menstrual period, independent of total body weight change. That means a woman can maintain her exact scale weight through perimenopause and still accumulate substantially more VAT. The scale is not telling you the full story.

Postmenopause

After menopause, VAT continues to accumulate but at a slower rate than during the transition itself. Postmenopausal women have VAT levels that, on average, approach those of age-matched men. This convergence partly explains the narrowing of the cardiovascular disease gap between women and men after age 55.

Hormone therapy timing matters here. The SWAN and the Kronos Early Estrogen Prevention Study (KEEPS) data suggest that estrogen-containing hormone therapy, when started within ten years of menopause or before age 60, attenuates VAT accumulation and preserves a more favorable fat distribution. This is one metabolic argument for timely hormone therapy initiation in eligible women, though the decision involves more than VAT alone.

VAT and Female-Specific Conditions

PCOS

Women with polycystic ovary syndrome carry disproportionately high VAT relative to their BMI. A meta-analysis of 16 studies found that women with PCOS had 30-40% greater VAT than BMI-matched controls without PCOS. The driver is hyperinsulinemia: elevated insulin upregulates lipoprotein lipase activity in visceral adipocytes while simultaneously promoting androgen synthesis, creating a feed-forward cycle between visceral fat and androgen excess.

If you have PCOS, your VAT risk threshold should be interpreted conservatively. Even a VAT area in the 80-100 cm² range warrants intervention in the context of PCOS.

Endometriosis

The relationship between VAT and endometriosis is complex. Women with endometriosis tend to have lower BMI and lower total body fat than the general population, but emerging data suggest that VAT-derived inflammation may worsen endometriosis-related pain and disease progression. Research in this area is still developing, and the evidence base is thin. Extrapolation from general inflammatory adipokine data applies here, but direct prospective studies in endometriosis populations are limited.

Postpartum

Pregnancy naturally increases VAT, particularly in the third trimester, as part of preparing metabolic reserves. A study in Obesity found that women who retained >5 kg of gestational weight gain at one year postpartum had significantly higher VAT than women who returned to pre-pregnancy weight. Postpartum VAT retention is a modifiable risk factor, and breastfeeding for at least six months is associated with faster VAT reduction.

Thyroid Disease

Hypothyroidism promotes VAT accumulation through reduced lipolysis and lower resting metabolic rate. Women with subclinical hypothyroidism (TSH 4.5-10 mIU/L) showed significantly higher VAT on DEXA compared with euthyroid controls in a cross-sectional study published in Thyroid. If your VAT is elevated and you have not had a recent thyroid panel, that is worth checking before attributing your VAT to lifestyle alone.

What High VAT Actually Means for Your Health

A single VAT score does not diagnose disease. It is a quantified risk signal. Here is what the evidence connects it to in women specifically.

Cardiometabolic Risk

The American Heart Association's scientific statement on obesity and cardiovascular disease identifies VAT as an independent predictor of atherosclerotic cardiovascular disease, separate from LDL cholesterol and blood pressure. High VAT raises triglycerides, lowers HDL, and drives small dense LDL particle formation, the atherogenic lipid pattern.

Insulin Resistance and Type 2 Diabetes

VAT adipocytes are more lipolytically active and more insulin-resistant than subcutaneous adipocytes. The Diabetes Prevention Program found that waist circumference, a crude proxy for VAT, predicted diabetes conversion more strongly in women than in men within the cohort. A direct VAT measurement sharpens that risk estimate considerably.

A practical clinical framework: think of VAT not as a weight measurement but as a metabolic fire alarm. It tells you what your fat is doing hormonally and biochemically, not just how much of it there is. The same total body fat percentage in two women, one with high VAT and low SAT and one with low VAT and high SAT, carries meaningfully different cardiometabolic risk. Most standard workups miss this distinction entirely.

Breast Cancer Risk

Adipose tissue is the primary site of peripheral estrogen synthesis after menopause. Epidemiological data from the Women's Health Initiative observational cohort found that postmenopausal women with higher VAT had a 35% greater risk of postmenopausal breast cancer compared with women in the lowest VAT quartile, a finding that persisted after adjusting for BMI.

Cognitive Health

VAT-derived inflammatory cytokines cross the blood-brain barrier and are associated with accelerated hippocampal atrophy and dementia risk. While the cognitive data is still maturing, a prospective study in the Annals of Internal Medicine found that midlife abdominal obesity predicted dementia risk 30 years later.

How to Lower VAT: What the Evidence Actually Shows in Women

High VAT is modifiable. The interventions below have evidence in female populations specifically.

Exercise: Type and Dose

Aerobic exercise reduces VAT even without caloric restriction. A randomized controlled trial by Irving et al. Found that high-intensity aerobic exercise (three to five sessions per week at 75-85% VO2 max) reduced VAT by 16-17% over 16 weeks in postmenopausal women with metabolic syndrome, with no change in total body weight in some participants.

Resistance training alone produces smaller VAT reductions but builds the muscle mass that improves insulin sensitivity. A combination approach outperforms either alone.

Dietary Pattern

Mediterranean-style eating and low-refined-carbohydrate diets both show VAT reduction in female cohorts. The PREDIMED trial found that adherence to a Mediterranean diet supplemented with olive oil or nuts reduced VAT area by approximately 6 cm² over five years compared with a low-fat control diet. Restricting ultra-processed foods and added sugar has the strongest effect on VAT relative to caloric reduction alone, partly because fructose is preferentially converted to hepatic and visceral fat.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce disproportionate reductions in VAT compared with subcutaneous fat. The SURMOUNT-1 trial found that tirzepatide at 15 mg reduced VAT by approximately 40% over 72 weeks in participants with obesity, with reductions in VAT exceeding reductions in total body weight percentage. Women with PCOS or perimenopausal weight gain are good candidates for this class when lifestyle modification is insufficient and eligibility criteria are met. See the WomanRx GLP-1 articles for dosing, eligibility, and female-specific side effect profiles.

Hormone Therapy in Perimenopause and Menopause

For eligible postmenopausal women, estrogen-containing hormone therapy attenuates the menopause-driven VAT increase. The effect is most pronounced with transdermal estradiol at doses of 0.05-0.1 mg/day. A randomized trial published in Menopause found that transdermal estradiol prevented the increase in VAT seen in the placebo group over 24 months of follow-up in recently postmenopausal women. Hormone therapy is not a primary VAT treatment, but VAT preservation is one of several metabolic considerations when weighing its use.

Sleep and Stress

Cortisol directly stimulates VAT accumulation through glucocorticoid receptors on visceral adipocytes. Sleep deprivation raises cortisol. A study in Sleep found that women who averaged <6 hours of sleep per night had 22% more VAT than women sleeping 7-8 hours, after controlling for total caloric intake. Chronic psychological stress compounds this through the same pathway.

Who Should Get a VAT Measurement?

Not everyone needs a DEXA VAT scan. This measurement adds the most value when:

• Your BMI is in the normal or overweight range but you have metabolic markers (elevated fasting glucose, high triglycerides, low HDL) suggesting hidden visceral adiposity
• You are perimenopausal or postmenopausal and gaining abdominal weight without scale change
• You have PCOS, and your treatment team wants to track metabolic response beyond weight
• You are considering or currently using a GLP-1 receptor agonist and want to track body composition change rather than just scale weight
• You have a strong family history of cardiovascular disease or type 2 diabetes and want a more precise risk baseline
• You are postpartum with retained gestational weight and want to understand where that weight is stored

Who Probably Does Not Need It Right Now

• Women with clearly elevated BMI (above 35) in whom VAT is very likely high and the clinical priority is intervention, not measurement
• Women without metabolic risk markers and with no family history, who are managing weight through lifestyle and feel well
• Pregnant women (scan should be deferred until postpartum)

Pregnancy and Lactation: Special Considerations

VAT measurement is not a test you seek during pregnancy. DEXA involves ionizing radiation, and while the dose is low (comparable to a transcontinental flight), there is no clinical reason to quantify VAT during pregnancy when the result would not change management. Defer the scan to at least six to twelve weeks postpartum.

During pregnancy, VAT physiologically increases as part of normal metabolic adaptation. The liver becomes mildly insulin-resistant in the second trimester to ensure glucose availability for the fetus. This is expected and not pathological unless it progresses to gestational diabetes.

Postpartum, the focus shifts to VAT retention. Women who had gestational diabetes, preeclampsia, or excessive gestational weight gain (>15 kg above IOM recommendations) are at elevated risk for postpartum VAT retention and subsequent metabolic syndrome. A baseline DEXA at three to six months postpartum can help quantify starting point if metabolic markers are abnormal.

Breastfeeding appears to accelerate postpartum VAT reduction. A prospective cohort study found that women who breastfed for six months or more had significantly lower VAT at one year postpartum compared with women who formula-fed from birth. This effect held after adjusting for postpartum dietary intake and physical activity.

Evidence Gaps: What We Do Not Yet Know in Women

Women have been underrepresented in body composition research. Most VAT reference ranges were derived from cohorts that were either predominantly male or did not stratify results by hormonal status. The practical gaps:

1. VAT thresholds for Asian women, Hispanic women, and Black women are not as well validated as those for white European women. The American Diabetes Association acknowledges that cardiometabolic risk in Asian individuals occurs at lower BMI and likely at lower VAT thresholds, but precise female-specific cut-points by ethnicity are not yet established.
2. How hormonal contraception changes VAT is understudied. Progestin-dominant contraceptives may partially counteract estrogen's VAT-suppressing effects, but direct DEXA studies in this population are sparse.
3. Long-term VAT trajectory data in women using GLP-1 receptor agonists are still accumulating. Most trials ran 72-104 weeks. Whether VAT rebound occurs after stopping treatment in women is not yet established.

These gaps are not reasons to avoid the test. They are reasons to interpret your result with a clinician who knows your hormonal context.